155 related articles for article (PubMed ID: 15114062)
1. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases.
Ochs HD; Pinciaro PJ;
J Clin Immunol; 2004 May; 24(3):309-14. PubMed ID: 15114062
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of an argentine intravenous immunoglobulin in pediatric patients with primary immunodeficiency diseases.
Krasovec S; Ornani A; Oleastro M; Rosenzweig S; Roy A; Perez L; Campos G; Marín N; Martinez A; Mahieu C; Manfredi MJ; Sisti A; Zelazko M
J Clin Immunol; 2007 Mar; 27(2):227-32. PubMed ID: 17235689
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials
.
Frenzel W; Wietek S; Svae TE; Debes A; Svorc D
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):847-855. PubMed ID: 27719744
[TBL] [Abstract][Full Text] [Related]
5. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases.
Berger M; Pinciaro PJ;
J Clin Immunol; 2004 Jul; 24(4):389-96. PubMed ID: 15163895
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.
Ballow M
Clin Exp Immunol; 2009 Sep; 157 Suppl 1(Suppl 1):22-5. PubMed ID: 19630866
[TBL] [Abstract][Full Text] [Related]
8. Tolerability and safety of the intravenous immunoglobulin octagam
Wietek S; Svorc D; Debes A; Svae TE
Hematology; 2018 May; 23(4):242-247. PubMed ID: 29020871
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma.
Berger M;
J Clin Immunol; 2007 Nov; 27(6):628-33. PubMed ID: 17909953
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin.
Brenner B
Clin Exp Rheumatol; 1996; 14 Suppl 15():S115-9. PubMed ID: 8828958
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
[TBL] [Abstract][Full Text] [Related]
14. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Engl W; Sharkhawy M; Leibl H; Puck J; Rubinstein A; Kobrynski L; Gupta S; Grant AJ; Ratnayake A; Richmond WG; Church J; Yel L; Gelmont D
J Clin Immunol; 2016 Aug; 36(6):571-82. PubMed ID: 27220317
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
17. Experience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141).
Dash C; Gascoigne E; Gillanders K; Gooi H
PLoS One; 2015; 10(7):e0131565. PubMed ID: 26222441
[TBL] [Abstract][Full Text] [Related]
18. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.
Robak T; Mainau C; Pyringer B; Chojnowski K; Warzocha K; Dmoszynska A; Straub J; Imbach P
Hematology; 2010 Oct; 15(5):351-9. PubMed ID: 20863431
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.
Berger M; Pinciaro PJ; Althaus A; Ballow M; Chouksey A; Moy J; Ochs H; Stein M
J Clin Immunol; 2010 Mar; 30(2):321-9. PubMed ID: 19997861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
